Relugolix is an oral GnRH receptor antagonist used for advanced prostate cancer. During medication, close attention should be paid to QT interval prolongation, hot flash management, and drug interactions to ensure medication safety.

I. QT Interval Prolongation

1.Risk Awareness

Relugolix may affect cardiac repolarization, leading to QT interval prolongation and increasing the risk of arrhythmia, especially in patients with pre-existing heart disease or electrolyte disturbances.

2.Pretreatment Evaluation

Before treatment, obtain a history of heart disease, arrhythmia, and syncope; perform an electrocardiogram when necessary, and test serum potassium and magnesium levels.

3.Caution in High-Risk Patients

Use with caution in patients with congenital long QT syndrome, uncorrected hypokalemia or hypomagnesemia, and heart failure; the doctor should weigh benefits and risks.

4.Vigilance with Concomitant Medications

Avoid concomitant use with other drugs that prolong the QT interval(such as certain antiarrhythmics, antipsychotics, and macrolide antibiotics); when concomitant use is necessary, strengthen electrocardiographic monitoring.

5.Symptom Monitoring

Seek medical attention immediately if palpitations, dizziness, syncope, or unexplained convulsions occur, to rule out arrhythmia.

II. Hot Flash Management

1.Understand the Characteristics

Hot flashes are a common reaction after hormone suppression, presenting as sudden warmth and sweating in the face, neck, and upper body; they recur and are mostly tolerable.

2.Lifestyle Adjustment

Keep the environment cool and wear breathable layered clothing; reduce triggers such as spicy foods, alcohol, caffeine, and hot drinks.

3.Regular Exercise

Moderate aerobic exercise helps regulate body temperature and mood; avoid strenuous activity during hot periods.

4.Seek Medical Attention Promptly

When hot flashes severely affect sleep or daily life, inform the doctor to assess whether intervention is needed; do not use hormone products on your own.

III. Drug Interactions

1.Avoid Concomitant Use with Strong Enzyme Inducers

Rifampin, carbamazepine, phenytoin, St. John's wort, etc., can accelerate the metabolism of relugolix and reduce efficacy; avoid concomitant use.

2.Use Enzyme Inhibitors with Caution

Strong CYP3A4 inhibitors may increase relugolix exposure and raise the risk of adverse reactions; when used together, doctor evaluation and monitoring are required.

3.Note P-gp Substrates

Relugolix can affect the blood concentration of P-glycoprotein substrate drugs(such as digoxin); monitor relevant indicators when used together.

4.Consult Before Combining Medications

Before starting any new drug(including prescription drugs, over-the-counter drugs, herbal medicines, and supplements), inform the doctor or pharmacist to confirm no interaction.

5.Regular Follow-up

During medication, recheck electrocardiogram, electrolytes, and liver function as advised; report abnormalities promptly, and do not adjust the dose or stop the medication on your own.